Abstract
Purpose: To evaluate the efficacy and safety of the AMP-1311, a newly developed polysulfone hemofilter (Asahi Kasei Medical Co. Ltd.), through the treatment with continuous hemofiltration (CHF) in patients with renal failure. Patients and methods: Sixty-eight patients requirng CHF treatment were enrolled from seven centers and 62 patients fulfilled the study. The efficacy was assesed by the ultrafiltrability and the removability of urea nitrogen and creatinine of the filter. The safety was assesed by the incidence associated with the treatment. Results: The filter demonstrated superb ultrafiltrability and removability. The filter achieved more than 80% of estimated ultrafiltration volume during the treatment. Moreover, it showed high stability as it was used more than 24 hours in most of the patients. The sieving coefficient was 0.99±0.12 (urea nitrogen) and 1.00±0.13 (creatinine). Sixty out of 62 patients revealed no adverse incidents during the treatment. Two patients showed hypotension and leukocytopenia during the treatment. However, these incidents were considered common in the treatment with blood purification. Thus, the filter was considered highly safe for the treament with CHF. Conclusion: The AMP-1311 filter is highly effective, stable and safe in the treatment with CHF.
